These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9260694)

  • 1. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
    Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
    J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer.
    Dillner L; Zellbi A; Avall-Lundqvist E; Heino P; Eklund C; Pettersson CA; Forslund O; Hansson BG; Grandien M; Bistoletti P
    Cancer Detect Prev; 1995; 19(5):381-93. PubMed ID: 7585724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based seroepidemiological study of cervical cancer.
    Dillner J; Lenner P; Lehtinen M; Eklund C; Heino P; Wiklund F; Hallmans G; Stendahl U
    Cancer Res; 1994 Jan; 54(1):134-41. PubMed ID: 8261434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
    Castellsagué X; Díaz M; de Sanjosé S; Muñoz N; Herrero R; Franceschi S; Peeling RW; Ashley R; Smith JS; Snijders PJ; Meijer CJ; Bosch FX;
    J Natl Cancer Inst; 2006 Mar; 98(5):303-15. PubMed ID: 16507827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
    Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients.
    Silins I; Avall-Lundqvist E; Tadesse A; Jansen KU; Stendahl U; Lenner P; Zumbach K; Pawlita M; Dillner J; Frankendal B
    Gynecol Oncol; 2002 May; 85(2):333-8. PubMed ID: 11972397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of seroreactive epitopes of human papillomavirus type 18 E7 protein by synthetic peptides.
    Krchnák V; Pistĕk T; Vágner J; Suchánková A; Kañka J; Ritterová L; Vonka V
    Acta Virol; 1993 Oct; 37(5):395-402. PubMed ID: 7514354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based study of cervical carcinoma and HPV infection in Latvia.
    Silins I; Wang X; Tadesse A; Jansen KU; Schiller JT; Avall-Lundqvist E; Frankendal B; Dillner J
    Gynecol Oncol; 2004 May; 93(2):484-92. PubMed ID: 15099967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for cervical neoplasia in Denmark.
    Kjaer SK
    APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
    Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
    J Infect Dis; 2000 Jun; 181(6):1911-9. PubMed ID: 10837170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women.
    Sasagawa T; Basha W; Yamazaki H; Inoue M
    Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):45-52. PubMed ID: 11205488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer.
    Nonnenmacher B; Pintos J; Bozzetti MC; Mielzinska-Lohnas I; Lorincz AT; Ikuta N; Schwartsmann G; Villa LL; Schiller JT; Franco E
    Int J STD AIDS; 2003 Apr; 14(4):258-65. PubMed ID: 12716496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-variable L1-peptide displays high sensitivity and specificity for detecting women having human papillomavirus-associated cervical lesions.
    Urquiza M; Guevara T; Sanchez R; Vanegas M; Patarroyo ME
    Peptides; 2008 Jun; 29(6):957-62. PubMed ID: 18294733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals.
    Masini C; Fuchs PG; Gabrielli F; Stark S; Sera F; Ploner M; Melchi CF; Primavera G; Pirchio G; Picconi O; Petasecca P; Cattaruzza MS; Pfister HJ; Abeni D
    Arch Dermatol; 2003 Jul; 139(7):890-4. PubMed ID: 12873884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
    Viscidi RP; Ahdieh-Grant L; Clayman B; Fox K; Massad LS; Cu-Uvin S; Shah KV; Anastos KM; Squires KE; Duerr A; Jamieson DJ; Burk RD; Klein RS; Minkoff H; Palefsky J; Strickler H; Schuman P; Piessens E; Miotti P
    J Infect Dis; 2003 Jan; 187(2):194-205. PubMed ID: 12552444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study.
    Hildesheim A; Han CL; Brinton LA; Kurman RJ; Schiller JT
    Obstet Gynecol; 1997 Nov; 90(5):748-54. PubMed ID: 9351758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus.
    Shields TS; Brinton LA; Burk RD; Wang SS; Weinstein SJ; Ziegler RG; Studentsov YY; McAdams M; Schiffman M
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1574-82. PubMed ID: 15466972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.
    Fisher SG; Benitez-Bribiesca L; Nindl I; Stockfleth E; Muller M; Wolf H; Perez-Garcia F; Guzman-Gaona J; Gutierrez-Delgado F; Irvin W; Gissmann L
    Gynecol Oncol; 1996 Apr; 61(1):73-8. PubMed ID: 8626121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological assays for the detection of HPV antibodies.
    Galloway DA
    IARC Sci Publ; 1992; (119):147-61. PubMed ID: 1330907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.